A Phase II, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety and Tolerability Study of SR57667B in Outpatients With Early Parkinson's Disease.

Trial Profile

A Phase II, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety and Tolerability Study of SR57667B in Outpatients With Early Parkinson's Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2009

At a glance

  • Drugs Paliroden (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jul 2009 Additional locations identified as reported by ClinicalTrials.gov.
    • 22 Dec 2008 Planned number of patients changed from 520 to 564 as reported by ClinicalTrials.gov.
    • 22 Dec 2008 Actual end date changed from Feb 2006 to Apr 2006 as reported by Clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top